Ildong, Cellivery To Co-Develop Novel Biologic For Parkinson's
This article was originally published in PharmAsia News
South Korean pharma firm Ildong and bioventure Cellivery have tied up to jointly develop an early stage, first-in-class therapy for Parkinson's disease using Cellivery's platform technology. The two hope the partnership will fundamentally change the therapeutic approach to the neurodegenerative disease.
You may also be interested in...
Marking the first Korean company to launch an initial public offering on the recommendation of its lead broker, Cellivery Therapeutics is slated to use the upcoming proceeds to progress preclinical trials of its lead assets for Parkinson's disease and pancreatic cancer, which the company aims to license out to global partners in the early development stages.
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.
As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.